Independent directory Public ClinicalTrials.gov records United States
Clear filters
ClinicalTrials.gov public records Last synced Sep 3, 2026, 7:19 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 63 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Conditions
Lung Cancer
Interventions
18F-FACBC Radiotracer
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
1
States / cities
Atlanta, Georgia
Conditions
Multiple Myeloma, Newly Diagnosed Multiple Myeloma (NDMM), Relapsed and/or Refractory Multiple Myeloma (RRMM)
Interventions
18F-fluciclovine injection, 18F-FDG PET/CT
Drug · Procedure
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 120 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2032
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Glioma
Interventions
18F-fluciclovine
Drug
Lead sponsor
James Mountz
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Conditions
Metastatic Castration-resistant Prostate Cancer
Interventions
18F-fluciclovine PET Scan
Drug
Lead sponsor
Tulane University
Other
Eligibility
18 Years to 18 Years · Male only
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
New Orleans, Louisiana
Completed Phase 2 Interventional Results available

FACBC Prostate Therapy Response

NCT02830880
Conditions
Prostate Cancer
Interventions
FACBC PET-CT, MRI, CT, or Bone Scan
Drug · Other
Lead sponsor
Emory University
Other
Eligibility
18 Years and older · Male only
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
Atlanta, Georgia
Conditions
Brain Metastases, Cancer, Gliomas, Glioblastoma
Interventions
F18 Fluciclovine, Standard of Care
Drug · Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2023
U.S. locations
1
States / cities
Houston, Texas
Conditions
Advanced Prostate Cancer, Metastatic Prostate Cancer, Metastatic Prostate Neuroendocrine Carcinoma
Interventions
18F-fluciclovine, PET/CT
Drug · Device
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older · Male only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
2
States / cities
Boston, Massachusetts
Conditions
Brain Tumor
Interventions
[18F]FLT, [18F]Fluciclovine
Drug
Lead sponsor
University of Utah
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
1
States / cities
Salt Lake City, Utah
Not listed No phase listed Observational Accepts healthy volunteers

Defining Recurrent Disease With Axumin™

NCT03996993
Conditions
Prostate Cancer, Prostate Adenocarcinoma
Interventions
Casodex, Axumin, Salvage Radiation, Axumin
Drug · Radiation
Lead sponsor
Cancer Center of Irvine
Other
Eligibility
18 Years and older · Male only
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Irvine, California
Conditions
Prostate Cancers
Interventions
anti [18F]FACBC
Drug
Lead sponsor
David M. Schuster, MD
Other
Eligibility
18 Years and older · Male only
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
1
States / cities
Atlanta, Georgia
Conditions
Brain Metastases
Interventions
18F fluciclovine
Drug
Lead sponsor
Blue Earth Diagnostics
Industry
Eligibility
18 Years and older
Enrollment
151 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
19
States / cities
Birmingham, Alabama • Phoenix, Arizona • San Francisco, California + 15 more
Conditions
Brain Metastases
Interventions
18F fluciclovine
Drug
Lead sponsor
Blue Earth Diagnostics
Industry
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
9
States / cities
Santa Monica, California • New Haven, Connecticut • Miami, Florida + 6 more
Completed Phase 2 Interventional Results available

FACBC for Recurrent Prostate Cancer

NCT01808222
Conditions
Recurrent Prostate Cancer
Interventions
FACBC
Drug
Lead sponsor
David M. Schuster, MD
Other
Eligibility
18 Years and older · Male only
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
Atlanta, Georgia
Conditions
Cervical Cancer, Endometrial Cancer, Ovarian Epithelial Cancer
Interventions
Fluciclovine F18
Drug
Lead sponsor
Bital Savir-Baruch
Other
Eligibility
18 Years and older · Female only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Maywood, Illinois
Completed Early Phase 1 Interventional Accepts healthy volunteers

18F-Fluciclovine PET/CT in the Assessment of Pancreatic Transplants

NCT04852523
Conditions
Pancreatitis, Graft, Pancreatic Transplant Post-Transplant Dysfunction Rejection
Interventions
18F-fluciclovine
Drug
Lead sponsor
University of Utah
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Salt Lake City, Utah
Conditions
Biochemically Recurrent Prostate Carcinoma, Metastatic Prostate Carcinoma, Prostate Adenocarcinoma, Stage IVB Prostate Cancer AJCC v8
Interventions
3-Dimensional Conformal Radiation Therapy, Apalutamide, Computed Tomography, Degarelix, External Beam Radiation Therapy, Fluciclovine F18, Goserelin Acetate, Intensity-Modulated Proton Therapy, Intensity-Modulated Radiation Therapy, Leuprolide Acetate, Magnetic Resonance Imaging, Positron Emission Tomography, Quality-of-Life Assessment, Questionnaire Administration, Relugolix, Stereotactic Body Radiation Therapy, Triptorelin, Volume Modulated Arc Therapy
Radiation · Drug · Procedure + 1 more
Lead sponsor
ECOG-ACRIN Cancer Research Group
Network
Eligibility
18 Years and older · Male only
Enrollment
804 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2032
U.S. locations
341
States / cities
Anchorage, Alaska • Fairbanks, Alaska • Phoenix, Arizona + 240 more
Conditions
Brain Metastases, Brain Metastases, Adult, Brain Cancer
Interventions
18F fluciclovine
Drug
Lead sponsor
Baptist Health South Florida
Other
Eligibility
18 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2033
U.S. locations
1
States / cities
Miami, Florida
Conditions
Prostate Cancer
Interventions
Standard of Care MRI, Fluciclovine PET scan added to MRI
Device · Other
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 100 Years · Male only
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
New York, New York
Conditions
Brain Metastases, Brain Cancer
Interventions
18F-Fluciclovine
Drug
Lead sponsor
Baptist Health South Florida
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2030
U.S. locations
1
States / cities
Miami, Florida
Conditions
Prostate Adenocarcinoma
Interventions
F-18 fluciclovine-PET/CT scan
Diagnostic Test
Lead sponsor
University of Arizona
Other
Eligibility
18 Years and older · Male only
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Tucson, Arizona
Conditions
Recurrent Prostate Carcinoma
Interventions
Computed Tomography, Fluciclovine F18, Gallium Ga 68-labeled PSMA-11, Laboratory Biomarker Analysis, Positron Emission Tomography
Procedure · Drug · Other
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
19 Years and older · Male only
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
1
States / cities
Los Angeles, California
Conditions
Glioma Glioblastoma Multiforme
Interventions
Axumin, Intravenous Solution
Drug
Lead sponsor
Ali Nabavizadeh
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Conditions
Anatomic Stage IV Breast Cancer AJCC v8, Invasive Breast Lobular Carcinoma, Metastatic Breast Lobular Carcinoma, Prognostic Stage IV Breast Cancer AJCC v8
Interventions
Computed Tomography, Fluciclovine F18, Gallium Ga 68 Gozetotide, Positron Emission Tomography
Procedure · Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Atlanta, Georgia
Completed Phase 2 Interventional Results available

High Resolution PET-MRI Before Prostate Cancer HIFU

NCT03263780
Conditions
Prostate Cancer
Interventions
18F-Fluciclovine
Drug
Lead sponsor
Timothy J. Daskivich
Other
Eligibility
18 Years and older · Male only
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Los Angeles, California